Futu Holdings (NASDAQ:FUTU) reported quarterly sales of $222.60 million which missed the analyst consensus estimate of $281.17 million by 20.83 percent. This is a 9.63 percent increase over sales of $203.05 million the same period last year.
Bloodbuy Announces Agreement With Cerus Corporation To Offer Pathogen Reduced Cryoprecipitated Fibrinogen Complex On Its Digital Marketplace
Bloodbuy, a healthcare software and services company focused on developing cloud-based technologies that transform how biological products are managed and disseminated, today announced that it has entered into an
